½ÃÀ庸°í¼­
»óǰÄÚµå
1602727

¼¼°èÀÇ ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀå : ÄÄÆ÷³ÍÆ®º°, ¿ëµµº° ¿¹Ãø(2025-2030³â)

Anatomic Pathology Testing Market by Component (Consumables, Instruments, Services), Application (Disease Diagnosis, Drug Discovery & Development) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀåÀº 2023³â¿¡ 424¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 450¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.22%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 647¾ï 4,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇØºÎÇÐ º´¸®ÇÐ °Ë»ç´Â ÀÇ·á Áø´Ü ºÎ¹®ÀÇ Áß¿äÇÑ ±¸¼º ¿ä¼ÒÀ̸ç Áúº´ Áø´Ü, Ä¡·á Áöħ ¹× ¿¬±¸¸¦À§ÇÑ Á¶Á÷ »ùÇà °Ë»ç¿¡ ÁßÁ¡À» µÓ´Ï´Ù. ƯÈ÷ Á¾¾çÇÐ, °¨ ¿°Áõ, Àå±â ÀÌ½Ä Æò°¡¿¡¼­ È¿°úÀûÀΠȯÀÚ °ü¸®¿¡ ÇʼöÀûÀÎ Á¤È®ÇÑ Áø´Ü Á¤º¸¸¦ Á¦°øÇϴ Ź¿ùÇÑ ´É·Â¿¡ ÀÖ½À´Ï´Ù. ½ÇÇè½Ç, Çмú ¿¬±¸ ±â°üÀÔ´Ï´Ù. ½ÃÀåÀº ¸¸¼º ÁúȯÀÇ À¯º´·ü »ó½Â, °í·ÉÈ­, ÀÇ·á ÀÇ½Ä Áõ°¡, µðÁöÅÐ º´¸®ÇÐ ¹× AI ÅëÇÕ µîÀÇ ±â¼ú Áøº¸ µîÀÇ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. »õ·Î¿î ¹ÙÀÌ¿À ¸¶Ä¿ÀÇ °³¹ßÀº ÁÖ¿ä ¼ºÀå ±âȸ¸¦ ³º°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¿ø°ÝÁö¿Í Àü¹®°¡°¡ ÀûÀº ±¹°¡¿¡¼­ ¿ø°Ý º´¸®ÇÐ ¼­ºñ½º¸¦ È®Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àå¾Ö¹°, ¼÷·Ã º´¸® ÀÇ»ç ºÎÁ·°ú °°Àº °úÁ¦´Â ½ÃÀå È®´ë¸¦ ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. µðÁöÅÐ º´¸®ÇÐÀÇ Áøº¸, AI ÁÖµµÀÇ Áø´Ü Åø, Á¤¹Ðµµ¿Í È¿À²À» Çâ»ó½ÃŰ´Â ÀÚµ¿ º´¸® °Ë»ç ±â±âÀÇ °³¹ß µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº ³ôÀº ±â¼úÀû ¿ªµ¿¼º°ú °æÀïÀÇ Ä¡¿­ÇÔÀ» Ư¡À¸·ÎÇϸç ÀÌÇØ °ü°èÀÚ´Â °æÀïÀ» È®º¸Çϱâ À§ÇØ ÆÄ±«Àû ±â¼ú°ú Àü·«Àû ÆÄÆ®³Ê½ÊÀ» äÅÃÇØ¾ßÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ (2023³â) 424¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2024³â) 450¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 647¾ï 4,000¸¸ ´Þ·¯
CAGR(%) 6.22%

½ÃÀå ¿ªÇÐ: ½Å¼ÓÇÏ°Ô ÁøÈ­ÇÏ´Â ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. °áÁ¤ÀÇ Á¤±³È­¿Í »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÏ´Â °ÍÀÌ ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ÀÌ´Â Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ¿í ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½Ä½À°üÀ̳ª ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­¿¡ ÀÇÇÑ Ç×¾ÏÁ¦ÀÇ ÀÓ»ó °Ë»ç °Ç¼ö Áõ°¡
    • ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñÀÇ °íÁ¶
    • ÀÓ»ó ¼¾ÅÍÀÇ Áø´Ü ÀýÂ÷ °³¼±¿¡ ´ëÇÑ ¼ö¿ä ±ÞÁõ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·
  • ½ÃÀå ±âȸ
    • ´ë»óÀ» Á¼Èù Ä¿¹ö¸®Áö¸¦ Á¦°øÇÏ´Â ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»çÀÇ Áøº¸
    • ¾Ç¼º Á¾¾ç°ú Á¾¾ç ¹ß»ýÀ» Á¶»çÇϱâ À§ÇÑ ¹ÙÀÌ¿À¸¶Ä¿º° º´¸®ÇÐÀû °Ë»ç¿Í ¼ö¼ú¿¡ ´ëÇÑ ½Å·Ú Áõ°¡
  • ½ÃÀåÀÇ °úÁ¦
    • Á¤ºÎ¿¡ ÀÇÇÑ ¾ö°ÝÇÑ ±ÔÄ¢°ú ±ÔÁ¦

Porter's Five Force : ÇØºÎÇÐ º´¸®ÇÐ °Ë»ç ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÇØºÎÇÐ º´¸®ÇÐ °Ë»ç ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÇØºÎÇÐ Àû º´¸®ÇÐ °Ë»ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ¼³¸íÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. À» ¿¹ÃøÇÏ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀå¿¡¼­ °æÀï ±¸µµ¸¦ ÆÄ¾Ç

ÇØºÎÇÐ º´¸®ÇÐ °Ë»ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁß, ºÎ¹®È­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í, º¥´õ´Â °æÀïÀÌ Ä¡¿­ÇØÁü¿¡ µû¶ó ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÕ´Ï´Ù. Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ÇØºÎÇÐ º´¸®ÇÐ °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÇØºÎÇÐ º´¸®ÇÐ °Ë»ç ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÃæºÐÇÑ Á¤º¸¸¦ ±â¹ÝÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ: ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇöÀå °­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ ´Ù·ç´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®¿¡¼­ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ¼³¸íÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾òÀº ÈÄ ÀÇ»ç°áÁ¤ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡µµ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ½Ä½À°üÀ̳ª ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­¿¡ ÀÇÇØ ¾Ï Ä¡·á¿¡ °üÇÑ ÀÓ»ó °Ë»ç°¡ Áõ°¡
      • ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñÀÌ ³ô¾ÆÁø´Ù
      • ÀÓ»ó ¼¾ÅÍÀÇ Áø´Ü ÀýÂ÷ °³¼±¿¡ ´ëÇÑ ¼ö¿ä ±ÞÁõ
    • ¾ïÁ¦¿äÀÎ
      • ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·
    • ±âȸ
      • ´ë»óÀ» Á¼Èù º¸µµ¸¦ Á¦°øÇÏ´Â ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»çÀÇ Áøº¸
      • ¾Ç¼º Á¾¾çÀ̳ª Á¾¾ç Çü¼ºÀ» Á¶»çÇϱâ À§ÇÑ ¹ÙÀÌ¿À¸¶Ä¿¿¡ ÀÇÇÑ º´¸® °Ë»ç³ª ½Ã¼ú¿¡ÀÇ ÀÇÁ¸µµ Áõ°¡
    • °úÁ¦
      • Á¤ºÎ¿¡ ÀÇÇÑ ¾ö°ÝÇÑ ±ÔÄ¢°ú ±ÔÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

  • ¼Ò°³
  • ¼Ò¸ðǰ
  • ±â±â
  • ¼­ºñ½º

Á¦7Àå ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀå : ¿ëµµº°

  • ¼Ò°³
  • Áúº´ÀÇ Áø´Ü
  • ÀǾàǰÀÇ ¹ß°ß°ú °³¹ß

Á¦8Àå ¾Æ¸Þ¸®Ä« ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀå

  • ¼Ò°³
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀå

  • ¼Ò°³
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÇØºÎÇÐÀû º´¸®ÇÐ °Ë»ç ½ÃÀå

  • ¼Ò°³
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company
  • Cardinal Health, Inc.
  • Danaher Corporation
  • Diapath SpA
  • Digipath, Inc.
  • Enzo Biochem, Inc.
  • Epic Sciences
  • Epredia
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Quest Diagnostics Incorporated
  • Sakura Finetek USA, Inc.
JHS 24.12.12

The Anatomic Pathology Testing Market was valued at USD 42.43 billion in 2023, expected to reach USD 45.03 billion in 2024, and is projected to grow at a CAGR of 6.22%, to USD 64.74 billion by 2030.

Anatomic pathology testing is a vital component of the medical diagnostics field, focusing on the examination of tissue samples to diagnose diseases, guide treatment, and conduct research. The necessity of anatomic pathology testing lies in its unparalleled ability to deliver precise diagnostic information essential for effective patient care, especially in oncology, infectious diseases, and organ transplant evaluations. The primary applications involve biopsy, surgical pathology, and cytopathology, with end-users comprising hospitals, diagnostic labs, academic and research institutes. The market is driven by factors like the rising prevalence of chronic diseases, the aging population, increasing healthcare awareness, and technological advancements such as digital pathology and AI integration. Key growth opportunities are emerging due to the surging demand for personalized medicine and the development of novel biomarkers that facilitate targeted therapy. There is also a potential in expanding telepathology services, especially in remote areas or countries with fewer specialized professionals. However, challenges such as the high cost of advanced diagnostic technologies, regulatory hurdles, and a shortage of skilled pathologists may inhibit market expansion. Furthermore, data privacy concerns and the need for robust IT infrastructure pose additional constraints. The best areas for innovation and research include advancements in digital pathology, AI-driven diagnostic tools, and the development of automated pathology equipment to improve accuracy and efficiency. Collaborations between technology firms and healthcare providers can enable the creation of integrated platforms that streamline workflow processes. As the anatomic pathology landscape evolves, focus on improving turnaround times, enhancing diagnostic accuracy, and integrating new technologies are crucial for stakeholders aiming to seize growing opportunities. The market is characterized by high technological dynamism and competitive intensity, urging stakeholders to adopt disruptive technologies and strategic partnerships to secure a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 42.43 billion
Estimated Year [2024] USD 45.03 billion
Forecast Year [2030] USD 64.74 billion
CAGR (%) 6.22%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anatomic Pathology Testing Market

The Anatomic Pathology Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the number of clinical trials pertaining to cancer drugs due to changes in food habits and lifestyle
    • Increasing focus on personalized medicine
    • Surge in demand to improve the diagnostic procedure in clinical centers
  • Market Restraints
    • Unavailability of skilled professionals
  • Market Opportunities
    • Advances in anatomic pathology testing providing targeted coverage
    • Growth in reliance on biomarkers-based pathology tests and procedures for exploring malignancy and tumorigenesis
  • Market Challenges
    • Strigent rules and regulations by the government

Porter's Five Forces: A Strategic Tool for Navigating the Anatomic Pathology Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anatomic Pathology Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anatomic Pathology Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anatomic Pathology Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anatomic Pathology Testing Market

A detailed market share analysis in the Anatomic Pathology Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anatomic Pathology Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anatomic Pathology Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anatomic Pathology Testing Market

A strategic analysis of the Anatomic Pathology Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anatomic Pathology Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, Cardinal Health, Inc., Danaher Corporation, Diapath S.p.A., Digipath, Inc., Enzo Biochem, Inc., Epic Sciences, Epredia, F. Hoffmann-La Roche AG, Hologic, Inc., Laboratory Corporation of America Holdings, Merck KGaA, Quest Diagnostics Incorporated, and Sakura Finetek USA, Inc..

Market Segmentation & Coverage

This research report categorizes the Anatomic Pathology Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Consumables, Instruments, and Services.
  • Based on Application, market is studied across Disease Diagnosis and Drug Discovery & Development.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the number of clinical trials pertaining to cancer drugs due to changes in food habits and lifestyle
      • 5.1.1.2. Increasing focus on personalized medicine
      • 5.1.1.3. Surge in demand to improve the diagnostic procedure in clinical centers
    • 5.1.2. Restraints
      • 5.1.2.1. Unavailability of skilled professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in anatomic pathology testing providing targeted coverage
      • 5.1.3.2. Growth in reliance on biomarkers-based pathology tests and procedures for exploring malignancy and tumorigenesis
    • 5.1.4. Challenges
      • 5.1.4.1. Strigent rules and regulations by the government
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anatomic Pathology Testing Market, by Component

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Instruments
  • 6.4. Services

7. Anatomic Pathology Testing Market, by Application

  • 7.1. Introduction
  • 7.2. Disease Diagnosis
  • 7.3. Drug Discovery & Development

8. Americas Anatomic Pathology Testing Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anatomic Pathology Testing Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anatomic Pathology Testing Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies Inc.
  • 3. Becton, Dickinson and Company
  • 4. Cardinal Health, Inc.
  • 5. Danaher Corporation
  • 6. Diapath S.p.A.
  • 7. Digipath, Inc.
  • 8. Enzo Biochem, Inc.
  • 9. Epic Sciences
  • 10. Epredia
  • 11. F. Hoffmann-La Roche AG
  • 12. Hologic, Inc.
  • 13. Laboratory Corporation of America Holdings
  • 14. Merck KGaA
  • 15. Quest Diagnostics Incorporated
  • 16. Sakura Finetek USA, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦